00:00:00 IGIHE NETWORK KINYARWANDA ENGLISH FRANCAIS

Rwanda rolls out first phase of MPox vaccination

By IGIHE
On 20 September 2024 at 10:15

Rwanda has officially launched the first phase of its MPox vaccination, targeting an initial group of 10,000 individuals. This phase prioritizes healthcare workers, cross-border traders, hotel staff, and other high-risk professionals who are more likely to contract the virus.

In a message shared on its social media platforms on the evening of September 19, 2024, the Ministry of Health emphasized that this vaccination effort is part of Rwanda’s ongoing strategy to prevent and combat the spread of MPox, a virus that has affected many African countries, including Rwanda, where cases have already been reported.

Julien Mahoro Niyingabira, spokesperson for the Ministry, recently told IGIHE that Rwanda’s approach to preventing MPox focuses on vaccinating those at greatest risk. He clarified, “We will not begin by vaccinating everyone. Certain groups are more vulnerable, and they will be prioritized based on vaccine availability. As the situation evolves, additional groups may also be considered for vaccination.”

The African Union is coordinating vaccine distribution across several African nations, assisting in the containment of MPox on the continent.

In Rwanda, all four individuals who contracted MPox in July have received treatment and been discharged. Health authorities have reassured the public that the country is well-equipped to manage and treat MPox cases, should more arise.

Meanwhile, the outbreak has significantly impacted the Democratic Republic of Congo (DRC), which has recorded over 22,000 cases and more than 715 deaths in 2024.

The virus has now spread to 22 of DRC’s 26 provinces and is present in 13 other African countries. In response, the World Health Organization (WHO) has allocated $600 million over six months to combat the virus globally.

Health officials continue to stress the importance of preventive measures such as frequent handwashing and avoiding sexual contact—both protected and unprotected—to prevent the virus’s transmission.

MPox symptoms typically manifest within three to fourteen days of infection and include a rash that primarily affects the face, hands, and genitals.

The rash begins as small fluid-filled blisters that dry out and form scabs as the patient heals. In addition to the rash, individuals may experience fever, fatigue, and weakness.

Recovery generally takes two to three weeks, and none of the patients treated in Rwanda have required prolonged hospitalization or succumbed to the virus.

Rwanda has reported cases of the less severe grade 1B strain of MPox, similar to that found in the DRC. In contrast, West Africa has seen cases of the more severe grade 2 strain.

Rwanda has officially launched the first phase of its MPox vaccination.
The first phase of MPox vaccination targets 10,000 individuals.

Advertisement

YOUR OPINION ABOUT THIS ARTICLE

RULES AND REGULATIONS
Kwamamaza